These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 38653622)

  • 1. No clinical benefit from sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) than BCG alone in the adjuvant treatment of high risk non muscle invasive bladder cancer: result of a planned interim analysis of a prospective randomized trial.
    Cicione A; Lombardo R; Nacchia A; Franco A; Simone G; Pastore A; Leonardo C; Franco G; Tubaro A; DE Nunzio C
    Minerva Urol Nephrol; 2024 Jun; ():. PubMed ID: 38842053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-803 Plus BCG Treatment for BCG-Naïve or -Unresponsive Non-Muscle Invasive Bladder Cancer: A Plain Language Review.
    Chamie K; Chang SS; Rosser CJ; Kramolowski E; Gonzalgo ML; Sexton WJ; Spilman P; Sender L; Reddy S; Soon-Shiong P
    Future Oncol; 2024 Jul; ():1-11. PubMed ID: 38953850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Percutaneous BCG enhances innate effector antitumor cytotoxicity during treatment of bladder cancer: a translational clinical trial.
    Ji N; Mukherjee N; Morales EE; Tomasini ME; Hurez V; Curiel TJ; Abate G; Hoft DF; Zhao XR; Gelfond J; Maiti S; Cooper LJN; Svatek RS
    Oncoimmunology; 2019; 8(8):1614857. PubMed ID: 31413921
    [No Abstract]   [Full Text] [Related]  

  • 4. Oncolytic adenoviral therapy plus pembrolizumab in BCG-unresponsive non-muscle-invasive bladder cancer: the phase 2 CORE-001 trial.
    Li R; Shah PH; Stewart TF; Nam JK; Bivalacqua TJ; Lamm DL; Uchio EM; Geynisman DM; Jacob JM; Meeks JJ; Dickstein R; Pearce SM; Kang SH; Jung SI; Kamat AM; Burke JM; Keegan KA; Steinberg GD
    Nat Med; 2024 Jun; ():. PubMed ID: 38844794
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic changes associated with Bacillus Calmette-Guerin (BCG) treatment in bladder cancer.
    Picard LC; Rich FJ; Kenwright DN; Stevens AJ
    Biochim Biophys Acta Rev Cancer; 2024 May; 1879(5):189123. PubMed ID: 38806074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Multinational, Multi-Institutional Study Assessing the Impact of Diabetes Mellitus on the Prognosis of Patients with Non-Muscle Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin.
    Abou Chakra M; Duquesne I; Peyromaure M; Mott SL; Moussa M; O'Donnell MA
    Nutr Cancer; 2024 Jul; ():1-9. PubMed ID: 38973234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Bladder-Related Medication in Non-Muscle Invasive Bladder Cancer Patients.
    Blichert-Refsgaard L; Graugaard-Jensen C; Nørgaard M; Jensen JB
    Cancers (Basel); 2024 May; 16(10):. PubMed ID: 38792014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative analysis of adverse events among intravesical drugs in bladder cancer: a real-world study on FAERS database.
    Peng Y; Song Y; Du Y; Qin C; Xu T
    Expert Opin Drug Saf; 2024 Jul; ():1-8. PubMed ID: 38946478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atypical B cells promote cancer progression and poor response to Bacillus Calmette-Guérin in non-muscle invasive bladder cancer.
    Yolmo P; Rahimi S; Chenard S; Conseil G; Jenkins D; Sachdeva K; Emon I; Hamilton J; Xu M; Rangachari M; Michaud E; Mansure JJ; Kassouf W; Berman DM; Siemens DR; Koti M
    Cancer Immunol Res; 2024 Jun; ():. PubMed ID: 38916567
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of atezolizumab in bacillus Calmette-Guérin-unresponsive high-risk non-muscle-invasive bladder cancer.
    Akinsola OA; Talwar R; Baskin A; Luckenbaugh AN; Al Hussein Al Awamlh B
    Transl Androl Urol; 2024 Jun; 13(6):1061-1063. PubMed ID: 38983471
    [No Abstract]   [Full Text] [Related]  

  • 11. Selecting the right treatment: Health outcome priorities in older patients with bladder cancer.
    Rutten VC; Al CM; Festen S; Zuiverloon TCM; Boormans JL; Polinder-Bos HA
    J Geriatr Oncol; 2024 Jul; 15(6):101811. PubMed ID: 38896950
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of Life in Patients with High-grade Non-muscle-invasive Bladder Cancer Undergoing Standard Versus Reduced Frequency of Bacillus Calmette-Guérin Instillations: The EAU-RF NIMBUS Trial.
    van Straten CGJI; Caris C; Grimm MO; Colombel M; Muilwijk T; Martínez-Piñeiro L; Babjuk MM; Türkeri LN; Palou J; Patel A; Bjartell AS; Witjes WPJ; van der Heijden AG; Kiemeney LALM
    Eur Urol Open Sci; 2023 Oct; 56():15-24. PubMed ID: 37822514
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of acupuncture to decrease adverse events in patients with high-risk non-muscle invasive bladder cancer receiving induction intravesical BCG therapy: Study protocol for a randomized, controlled pilot and feasibility study.
    Psutka SP; Veleber S; Siman J; Jannat S; Holt S; Wright JL; Greenlee H
    Contemp Clin Trials Commun; 2022 Dec; 30():101044. PubMed ID: 36561732
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14.
    Rentsch CA; Thalmann GN; Lucca I; Kwiatkowski M; Wirth GJ; Strebel RT; Engeler D; Pedrazzini A; Hüttenbrink C; Schultze-Seemann W; Torpai R; Bubendorf L; Wicki A; Roth B; Bosshard P; Püschel H; Boll DT; Hefermehl L; Roghmann F; Gierth M; Ribi K; Schäfer S; Hayoz S
    Eur Urol Oncol; 2022 Apr; 5(2):195-202. PubMed ID: 35012889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
    Shepherd AR; Shepherd E; Brook NR
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
    [TBL] [Abstract][Full Text] [Related]  

  • 16. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.
    Babjuk M; Burger M; Compérat EM; Gontero P; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Zigeuner R; Capoun O; Cohen D; Escrig JLD; Hernández V; Peyronnet B; Seisen T; Soukup V
    Eur Urol; 2019 Nov; 76(5):639-657. PubMed ID: 31443960
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1/2 Randomized Clinical Trial of In-clinic acupuncture Prior to Bacillus Calmette-Guérin in Patients with High-risk Non-muscle-invasive Bladder Cancer.
    Psutka SP; Veleber S; Siman J; Holt SK; Jannat S; Wright JL; Lin DW; Gore JL; Schade GR; Annen Z; Greenlee H
    Eur Urol Oncol; 2024 Apr; ():. PubMed ID: 38653622
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.